期刊文献+

苯那普利对不同程度肾性蛋白尿的疗效分析 被引量:8

Analysis of the effect of Benazepril in patients with different levels of renal proteinuria
下载PDF
导出
摘要 目的 探讨苯那普利对不同程度肾性蛋白尿疗效的差异。方法 61例不同程度蛋白尿患者服用苯那普利20~30mg/d,观察12周,治疗前、后定期监测血压、尿蛋白、肝功能、肾功能及血钾。结果 尿蛋白〈3g/d的41例患者治疗后,33例转阴,3例有效,总有效率为88%;尿蛋白≥3g/d的20例患者治疗后,6例转阴,4例治疗有效,总有效率为50%。结论 苯那普利对不同程度肾性蛋白尿均有治疗效果,尿蛋白〈3g/d患者较≥3g/d者疗效更佳。 Objective To investigate the effect of P, enazepril in patients with proteinuria in different levels. Method 61 cases with proteinuria received P, enazepril 20-30 mg/d. The treatment las- ted for 12 weeks and the parameters of blood pressure, proteinuria, liver function, renal function and serum potassium were detected before and after treatment. Results After treatment, 33 cases turned to negative, 3 cases were effective and the total effective rate was 88% in 41 cases with 24-hour proteinuria excretion below 3.0g; 6 cases turned to negative,4 cases were effective and the total effective rate was 50% in 20 cases with 24-hour proteinuria excretion over 3.0g. Conclusions P, enazepril is an effective measure for patients with renal proteinuria in different levels, especially for those with 24-hour proteinuria excretion below 3. 0g.
出处 《临床肾脏病杂志》 2005年第4期167-168,共2页 Journal Of Clinical Nephrology
  • 相关文献

参考文献3

二级参考文献29

  • 1Ahola H, Wang SX, Luimula P, et al.Cloning and expression of the rat nephrin homolog. Am J Pathol, 1999, 155:907 -913.
  • 2Hulthen UL. Nephrin: a pivotal molecule in proteinuria influenced by angiotensin Ⅱ.J Hypertens, 2003, 21: 39-40.
  • 3Kelly DJ, Aaltonen P, Cox AJ, et al.Expression of the slit-diaphragm protein,nephrin, in experiment diabetic nephropathy: differing effects of anti-proteinuric therapies. Nephrol Dial Transplant, 2002,17: 1327-1332.
  • 4Keane WF, Brenner BM, De Zeeuw D, et al: The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL Study. Kidney Int 2003: 63: 1499-1507.
  • 5Klahr S and Morrissey JJ:The role of vasoactive compounds, growth factors and cytokines in the progression of renal disease. Kidney Int 2000; supp175: s7-s 14.
  • 6Jianzhong Wang, Feng Zhou, Xiangmei Chen, et al: Signal transducer and activator of transcription (STAT) pathway mediates up-regulation of expression of tissue inhibitor of metalloproteinase- 1 induced by angiotensin Ⅱ in human proximal tubular epithelial cell. J Am Soc Nelhro. 2002;13: F-P0141.
  • 7Lewis EJ,Hunsicker LG,Clarke WR,et al: Renoprotective effect of the angiotensinreceptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.N Engl J Med 2001; 345: 851-860.
  • 8Edmund J. Lewis, M. D, Lawrence G., et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Eng1 J Med 2001: 345: 851-860.
  • 9Hene RJ, Boer P. Koomans HA, et al: Plasma aldosterone concentrations in chronic renal disease. Kidney Int 1982; 21: 98-101.
  • 10Rocha R, Chander PN, Zuckerman A, et al: Role ofaldosterone in renal vascular iniury in stroke-prone hypertensive rats. Hypertension 1999 ; 33: 232-237.

共引文献15

同被引文献39

引证文献8

二级引证文献64

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部